重组抗HIV CD4结合位点单克隆抗体(3BNC117) 人IgG1 Kappa | Syd Labs PA007178

重组抗HIV CD4结合位点单克隆抗体(3BNC117) 人IgG1 Kappa Syd Labs PA007178

重组抗HIV CD4结合位点单克隆抗体(3BNC117) 人IgG1 Kappa | Syd Labs PA007178

In stock

一键复制

Syd Labs生产的体内实验级重组抗HIV CD4结合位点单克隆抗体(克隆3BNC117)为哺乳动物细胞表达的全长人IgG1 Kappa抗体,是VRC01类广谱中和抗体的代表成员,靶向HIV-1 gp120上保守的CD4结合位点(CD4bs),通过模拟CD4受体结合并结合N276糖基以识别融合前闭合态Env三聚体,对约80%跨亚型HIV-1分离株具高中和活性(几何平均IC50约0.07–0.17 μg/mL),是最早进入人体临床试验并证实单药/联合治疗(如与10-1074联用)可显著抑制病毒载量、延缓病毒反弹的HIV bNAb之一,适用于HIV-1中和实验、Env结构生物学、CD4bs靶向机制研究、ADCC及体内被动免疫/治疗功能实验。

产品参数

货号 PA007178
产品名称重组抗HIV CD4结合位点单克隆抗体(3BNC117) 人IgG1 Kappa | Syd Labs PA007178
英文名 In Vivo Grade Recombinant Anti-HIV CD4-Binding Site Monoclonal Antibody (Clone 3BNC117), Human IgG1 Kappa
供货商名称 Syd Labs, Inc.
品牌名 Syd Labs
克隆号 3BNC117
同种型 人IgG1 Kappa
反应性 HIV-1(跨亚型,约 80% 分离株被中和,几何平均 IC50 约 0.07–0.17 μg/mL)
特异性 HIV gp120 CD4结合位点(CD4-binding site,CD4bs)
抗体形式 0.2 μm 过滤的 1× PBS 溶液
内毒素 <1 EU/mg(LAL 法测定)
纯度 >95%(还原性 SDS-PAGE)
运输 冰袋运输,收到后请立即按推荐条件储存
稳定性与存储 使用手动除霜冰箱并避免反复冻融循环。2-8℃自收到之日起可保存1个月;-20℃至-70℃自收到之日起可保存12个月,建议分装保存
产品咨询 Syd Labs在国内只通过代理商销售其产品,不做直销。终端用户咨询价格请联系Syd Labs中国代理商。
关于Syd Labs产品如果有任何技术或其它问题,欢迎随时联系Syd Labs国内市场推广合作伙伴:武汉多找找科技有限公司,企业微信:duozhaozhao2024 联系电话:18162581039(龙经理)
应用详情 ELISA、Western blot、免疫组化(IHC)、流式细胞术(FC)、HIV-1 中和实验、ADCC、结构生物学、被动免疫/治疗研究、抗体联合疗法与病毒反弹/逃逸机制研究及多种体内外功能实验

文献

重组抗HIV CD4结合位点单克隆抗体(3BNC117) 人IgG1 Kappa,体内实验级(In Vivo Grade Recombinant Anti-HIV CD4-Binding Site Monoclonal Antibody (Clone 3BNC117), Human IgG1 Kappa)

重组抗HIV CD4结合位点单克隆抗体背景知识:

HIV-1 包膜糖蛋白 Env(gp120-gp41 三聚体)是病毒表面唯一可被抗体直接识别的抗原,而 CD4 结合位点(CD4bs)是其中最保守、最受关注的广谱中和表位之一——它位于 gp120 外域的凹陷处,是宿主 CD4 受体的天然结合位点,也是 VRC01、NIH45-46、3BNC117、VRC07-523、N6 等 VRC01 类广谱中和抗体(bnAb)共同靶向的位点。这类抗体的重链 VH1-2 基因区段模拟 CD4 的 β-发夹插入 CD4bs 口袋,轻链则进化出绕开或结合 N276 糖基的能力,从而克服 Env 的糖基屏蔽,实现跨亚型广谱中和。

克隆 3BNC117 由 Nussenzweig、Bjorkman 等团队于 2011 年从一名精英中和者中分离,是 VRC01 类抗体中较早被推进临床的代表分子。与 VRC01 相比,3BNC117 的中和广度约覆盖 80% 的跨亚型 HIV-1 分离株,几何平均 IC50 达亚纳摩尔至低纳摩尔级(约 0.07–0.17 μg/mL),体细胞高突变水平略高于 VRC01,对部分 VRC01 耐药株仍保持活性;其 Fab 与 gp120 复合物的晶体结构显示,3BNC117 通过重链 CDR H2 模拟 CD4 的 Phe43 接触 gp120 的 CD4bs loop,同时 CDR L3 与 N276 糖基形成氢键,典型地体现了 VRC01 类抗体”模拟 CD4 + 容纳/识别 N276 糖基”的双元件识别机制。

在临床研究方面,3BNC117 是最早完成 I/II 期人体试验并系统证明 HIV 抗体单药与联合治疗有效性的广谱中和抗体之一:2015 年 Nature 研究首次显示单剂 3BNC117 输注可使 HIV 感染者血浆病毒载量下降 0.8–2.5 log10 copies/mL、抑制持续数周;2018 年与 10-1074 联用的组合疗法在 cART 中断后维持中位 21 周病毒抑制,为 HIV 抗体介导缓解(antibody-mediated remission)和”功能治愈”策略提供了关键临床证据;此外 3BNC117 在人源化小鼠和 SHIV 恒河猴模型中也被广泛用于评估被动预防和治疗性保护效果。

本品为体内实验级(In Vivo Grade)制剂,来源于哺乳动物细胞表达的重组全长人 IgG1 Kappa,内毒素低于 1 EU/mg、配方为无防腐剂的 1× PBS,适合用于 HIV-1 中和实验、CD4bs 表位识别与 N276 糖基依赖性机制研究、Env 结构生物学辅助、ADCC 等效应功能实验、SHIV/HIV 人源化小鼠或非人灵长类体内被动保护/治疗研究,以及单药/联合抗体疗法的临床前评估。使用前请根据实验体系确定工作浓度,并避免反复冻融。

重组抗HIV CD4结合位点单克隆抗体参考文献:

1.Broad neutralization coverage of HIV by multiple highly potent antibodies Johannes F Scheid,et al.Nature. 2011.PMCID: PMC3096833 “The isolation of human monoclonal antibodies that potently neutralize a broad range of HIV-1 isolates has generated renewed interest in antibody-based prevention and therapy, and provided templates for vaccine design. Here we describe a panel of broadly neutralizing antibodies (bNAbs) from HIV-infected individuals that includes two, 3BNC117 and 3BNC60, that target the CD4-binding site of gp120 and neutralize 80-90% of circulating HIV-1 isolates with an average IC(50) of 0.03-0.07 μg/ml. Crystal structures of 3BNC117 Fab in complex with gp120 reveal that this antibody mimics CD4 recognition and accommodates the N276 glycan through a short CDR L3 loop, providing a structural basis for its exceptional breadth and potency. These antibodies represent a new generation of CD4-binding-site-directed bNAbs that are substantially more potent and broader than their predecessors.”

2. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys Dan H Barouch,et al.Nature. 2013.PMCID: PMC3571847 “Human monoclonal antibodies (mAbs) that potently neutralize diverse HIV-1 isolates represent potential agents for the prevention and treatment of HIV-1 infection. Here we evaluate the therapeutic efficacy of the highly potent and broadly neutralizing CD4-binding-site-directed mAb 3BNC117, as well as VRC01 and VRC03, in rhesus monkeys chronically infected with the R5-tropic simian-human immunodeficiency virus SHIV-SF162P3. A single intravenous infusion of 3BNC117 led to a rapid 1-2 log(10) reduction in plasma viraemia that was sustained for 14-28 days in most animals, and was associated with increased CD4+ T cell counts. Viral rebound following antibody clearance was accompanied by sequence changes in Env consistent with escape from 3BNC117. These data demonstrate therapeutic activity of bNAbs in a primate model of HIV-1 infection and support the clinical development of 3BNC117 for HIV-1 therapy.”

3. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 Marina Caskey,et al.Nature. 2015.PMCID: PMC4411193 “HIV-1 immunotherapy with broadly neutralizing antibodies (bNAbs) is a promising alternative or complement to combination antiretroviral therapy (cART), but data from human trials remain limited. We conducted a phase 1 dose-escalation trial of a single 1, 3, 10 or 30 mg/kg intravenous infusion of the CD4-binding-site bNAb 3BNC117 in HIV-1-infected individuals not receiving cART. Infusions were well tolerated, and the highest dose resulted in a 0.8 to 2.5 log(10) reduction in plasma HIV-1 RNA relative to baseline in participants with antibody-sensitive virus, with viraemic suppression maintained for up to 28 days. Viral rebound was associated with the emergence of resistant viruses carrying mutations in the 3BNC117 contact surface of gp120. These data demonstrate that a single bNAb infusion can exert strong antiviral activity in humans and support the development of combination bNAb therapies.”

4. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1 Till Schoofs,et al.Science. 2016.PMCID: PMC5062932 “3BNC117 is a broad and potent anti-HIV-1 neutralizing antibody that targets the CD4-binding site of the viral envelope glycoprotein. In addition to direct virus neutralization, antibodies may mediate antiviral effects through Fc-dependent effector functions and potentiation of host immune responses. Here we show that administration of a single dose of 3BNC117 to HIV-1-infected individuals not only reduced viral load but also augmented host humoral immune responses against HIV-1, as evidenced by increased autologous neutralizing antibody titres and enhanced antibody-dependent cellular cytotoxicity (ADCC) activity against autologous virus. These findings suggest that therapeutic bNAbs may act as immunotherapeutic agents that both suppress virus and help to elicit or boost endogenous anti-HIV-1 immunity, providing a rationale for combining passive antibody therapy with strategies aimed at inducing or augmenting host immune responses.”

5. Combination therapy with anti-HIV-1 antibodies maintains viral suppression Yotam Bar-On,et al.Nature. 2018.PMCID: PMC6004374 “HIV-1-infected individuals on suppressive combination antiretroviral therapy (cART) interrupt treatment at substantial risk of viral rebound. Single infusions of the CD4-binding-site bNAb 3BNC117 or the V3-glycan-targeting bNAb 10-1074 each transiently delay rebound after cART interruption. Here we show that up to three doses of the combination of 3BNC117 and 10-1074 maintained viraemic suppression for a median of 21 weeks after cART cessation in a phase 1b clinical trial (range 5 to >30 weeks). Combination antibody therapy was well tolerated and selected for viruses that were resistant to both antibodies only after weeks of suppression; post-hoc analyses revealed that individuals with pre-existing dual-sensitive virus maintained suppression longest. These findings demonstrate that combination bNAb therapy can provide long-term immunological control of HIV-1 in the absence of cART and provide proof-of-concept for antibody-mediated HIV-1 remission strategies.”